)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
TScan Therapeutics (TCRX) investor relations material
TScan Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 27th Annual Global Investment Conference summary10 Sep, 2025
Key clinical program updates
Lead heme malignancy program showed an 8% relapse rate in treated patients versus 33% in controls, prompting advancement to a pivotal trial this year.
Updated phase one data and longer-term follow-up will be presented at a major medical conference at year-end.
Pivotal trial will use TSC-101, with a synthetic control arm from the CIBMTR database, aiming for top-line data by end of 2027.
Expansion to additional HLA types is underway, with two new TCRs in IND-enabling activities and more in discovery.
$218 million in cash provides runway into Q1 2027.
Clinical data and safety
Phase one study included 26 treated and 12 control patients, with balanced high-risk profiles between arms.
Treatment was well tolerated, with no increase in adverse events compared to controls; only mild, manageable CRS observed.
Treated patients showed higher rates of complete donor chimerism and sustained MRD negativity post-infusion.
Substantial reduction in relapse rates observed, supporting progression to pivotal trial.
Market opportunity and expansion
Initial addressable market is ~1,300 patients/year in the US and Europe, with potential to expand to over 5,000 as clinical practice shifts.
Expansion to additional HLA types could double the market, with further opportunities to reach over 15,000 patients annually.
Pivotal trial: FDA view on synthetic control arm?
How to drive haploidentical donor market shift?
How will multiplex therapy overcome heterogeneity?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next TScan Therapeutics earnings date
Q3 202511 Nov, 2025
Next TScan Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage